These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21296701)

  • 1. Open- and closed-loop multiobjective optimal strategies for HIV therapy using NSGA-II.
    Heris SM; Khaloozadeh H
    IEEE Trans Biomed Eng; 2011 Jun; 58(6):1678-85. PubMed ID: 21296701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A model predictive control strategy toward optimal structured treatment interruptions in anti-HIV therapy.
    Pannocchia G; Laurino M; Landi A
    IEEE Trans Biomed Eng; 2010 May; 57(5):1040-50. PubMed ID: 20172797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of HAART with genetic algorithms and agent-based models of HIV infection.
    Castiglione F; Pappalardo F; Bernaschi M; Motta S
    Bioinformatics; 2007 Dec; 23(24):3350-5. PubMed ID: 17942443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hybrid optimal control for HIV multi-drug therapies: a finite set control transcription approach.
    Thakur D; Marchand B
    Math Biosci Eng; 2012 Oct; 9(4):899-914. PubMed ID: 23311427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimized structured treatment interruption for HIV therapy and its performance analysis on controllability.
    Ko JH; Kim WH; Chung CC
    IEEE Trans Biomed Eng; 2006 Mar; 53(3):380-6. PubMed ID: 16532764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A game theoretical approach to optimal control of dual drug delivery for HIV infection treatment.
    Wu J; Zhang M
    IEEE Trans Syst Man Cybern B Cybern; 2010 Jun; 40(3):694-702. PubMed ID: 20176541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taking side effects into account for HIV medication.
    Costanza V; Rivadeneira PS; Biafore FL; D'Attellis CE
    IEEE Trans Biomed Eng; 2010 Sep; 57(9):2079-89. PubMed ID: 20501345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When to initiate HIV therapy: a control theoretic approach.
    Jeffrey AM; Xia X; Craig IK
    IEEE Trans Biomed Eng; 2003 Nov; 50(11):1213-20. PubMed ID: 14619991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative evaluation of open loop and closed loop drug administration strategies in the treatment of AIDS.
    Caetano MA; Yoneyama T
    An Acad Bras Cienc; 1999; 71(4 Pt 1):589-97. PubMed ID: 10683672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting differential responses to structured treatment interruptions during HAART.
    Bajaria SH; Webb G; Kirschner DE
    Bull Math Biol; 2004 Sep; 66(5):1093-118. PubMed ID: 15294419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of nonlinear filtering approaches in the context of an HIV model.
    Banks HT; Hu S; Kenz ZR; Tran HT
    Math Biosci Eng; 2010 Apr; 7(2):213-36. PubMed ID: 20462287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonlinear control of a dynamic model of HIV-1.
    Ge SS; Tian Z; Lee TH
    IEEE Trans Biomed Eng; 2005 Mar; 52(3):353-61. PubMed ID: 15759565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-objective reliability-based optimization with stochastic metamodels.
    Coelho RF; Bouillard P
    Evol Comput; 2011; 19(4):525-60. PubMed ID: 21281119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Criteria for initiating highly active antiretroviral therapy and short-term immune response among HIV-1-infected patients in Côte d'Ivoire.
    Diabaté S; Alary M
    HIV Med; 2009 Nov; 10(10):640-6. PubMed ID: 19659945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
    Castagna A; Galli L; Torti C; D'Arminio Monforte A; Mussini C; Antinori A; Cozzi-Lepri A; Ladisa N; De Luca A; Seminari E; Gianotti N; Lazzarin A
    Antivir Ther; 2010; 15(2):165-75. PubMed ID: 20386071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining convergence and diversity in evolutionary multiobjective optimization.
    Laumanns M; Thiele L; Deb K; Zitzler E
    Evol Comput; 2002; 10(3):263-82. PubMed ID: 12227996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.
    Stone SF; Price P; French MA
    HIV Med; 2005 Jul; 6(4):278-83. PubMed ID: 16011533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation.
    Molina-Pinelo S; Vallejo A; Díaz L; Soriano-Sarabia N; Ferrando-Martínez S; Resino S; Muñoz-Fernández MA; Leal M
    J Antimicrob Chemother; 2009 Sep; 64(3):579-88. PubMed ID: 19608579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.